GILD vs LYEL
GILD: A leading biopharmaceutical innovator specializing in life-saving HIV therapies and complex CAR T-cell cancer treatments. LYEL: Lyell Immunopharma is developing next-generation, engineered CAR T-cell therapies designed to provide durable, curative responses in hematologic and solid tumor cancers.
Side-by-side fundamentals
| Metric | GILD | LYEL | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $147.10 | $8.79 | |
| Market cap | $182.4B | $215M | |
| Net margin FY2025, SEC XBRL | +28.9% | -762355.6% | GILD higher |
| Operating margin FY2025, SEC XBRL | +34.0% | -748344.4% | GILD higher |
| ROE FY2025, SEC XBRL | +37.6% | -110.6% | GILD higher |
| ROA FY2025, SEC XBRL | +14.4% | -80.7% | GILD higher |
| Debt / equity as of 2026-09-03 | 2.22 | 0.00 | LYEL lower |
| Revenue growth (YoY) as of 2026-09-03 | +5.5% | -52.3% | GILD higher |
| Revenue CAGR (3y) SEC XBRL | +2.6% | -92.5% | GILD higher |
| Dividend yield as of 2026-09-03 | +2.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 11 | 0 | GILD higher |
| Beta as of 2026-09-03 | 0.37 | 1.31 | |
| 1-year return as of 2026-10-08 close | +24.4% | -51.9% | GILD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.